- Home
- ILLR vs OMER Comparison
ILLR vs OMER Comparison
Compare ILLR & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- OMER
- Stock Information
- Founded
- ILLR 2015
- OMER 1994
- Country
- ILLR United States
- OMER United States
- Employees
- ILLR N/A
- OMER N/A
- Industry
- ILLR Investment Managers
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- ILLR Finance
- OMER Health Care
- Exchange
- ILLR Nasdaq
- OMER Nasdaq
- Market Cap
- ILLR 644.2M
- OMER 667.0M
- IPO Year
- ILLR N/A
- OMER 2009
- Fundamental
- Price
- ILLR $2.25
- OMER $10.31
- Analyst Decision
- ILLR
- OMER Buy
- Analyst Count
- ILLR 0
- OMER 3
- Target Price
- ILLR N/A
- OMER $9.00
- AVG Volume (30 Days)
- ILLR 712.4K
- OMER 1.4M
- Earning Date
- ILLR 02-15-2025
- OMER 11-13-2024
- Dividend Yield
- ILLR N/A
- OMER N/A
- EPS Growth
- ILLR N/A
- OMER N/A
- EPS
- ILLR N/A
- OMER N/A
- Revenue
- ILLR $45,244,000.00
- OMER N/A
- Revenue This Year
- ILLR N/A
- OMER N/A
- Revenue Next Year
- ILLR N/A
- OMER N/A
- P/E Ratio
- ILLR N/A
- OMER N/A
- Revenue Growth
- ILLR N/A
- OMER N/A
- 52 Week Low
- ILLR $0.66
- OMER $2.61
- 52 Week High
- ILLR $8.86
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- ILLR N/A
- OMER 58.84
- Support Level
- ILLR N/A
- OMER $7.20
- Resistance Level
- ILLR N/A
- OMER $13.60
- Average True Range (ATR)
- ILLR 0.00
- OMER 1.38
- MACD
- ILLR 0.00
- OMER -0.30
- Stochastic Oscillator
- ILLR 0.00
- OMER 48.59
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.